Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Fig. 2

Results of the high-throughput multi-step drug combination screening with 9 days of epigenetic pretreatment. a An example of a compound that induced sensitization to rituximab and doxorubicin vs. phosphate-buffered saline (PBS). The combination induced 50% growth inhibition at 1000 nM concentration, which is not seen with monotreatment with entinostat. The main aim of this report is to identify such sensitizising compounds. b An example of a compound that does not sensitize cells to rituximab and doxorubicin, but has a cytotoxic effect. c Summary of the reprogramming screening hits of 60 compounds across four DLBCL cell lines. Reprogramming scores above a threshold of 30% (see Materials and Methods) and whose dose-response curve passed quality inspection are considered as hits and marked in orange. Ten compounds, marked in bold, were selected for the synergy assay based on their reprogramming potential and mechanisms of action. All dose response curves are available in Results Explorer (http://app.anduril.org/DLBCL_DSRT)

Back to article page